Abstract: Disclosed is a novel class of compounds of formula (I)
wherein V, A, Y, Z, R1, E, X and D are as defined in the specification. These compounds act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor, the compounds are suitable for treating or preventing glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
Type:
Grant
Filed:
May 16, 2000
Date of Patent:
January 7, 2003
Assignee:
Noro Nordisk A/S
Inventors:
Jesper Lau, Peter Madsen, Christian Sams, Carsten Behrens, Josef Vagner, Inge Thøger Christensen, Behrend Frederik Lundt, Ulla Grove Sidelmann, Henning Thøgersen, Anthony L. Ling, Michael Bruno Plewe, Larry Kenneth Truesdale, Shenghua Shi
Abstract: Provided is a method for acylating one or more amino groups of a peptide or protein such as GLP-1. This method includes (a) reacting a peptide or protein having at least one free amino group with an acylating agent of formula I
wherein n is 0-8; R1 is COOR4; R2 is a lipophilic moiety; R3 and its attached carboxyl group designate a reactive ester or a reactive N-hydroxy imide ester; and R4 is selected from hydrogen, C1-12-alkyl and benzyl, under basic conditions in a mixture of an aprotic polar solvent and water; and (b) if R4 is not hydrogen, saponifying the acylated peptide or protein ester group under basic conditions in order to obtain an N-acylated peptide or an N-acylated protein.